• Chia-Lin Lee and Jun-Sing Wang.
• MD, PhD. Assistant Professor, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
• Sao Paulo Med J. 2019 Nov 1; 137 (6): 523529523-529.

BackgroundFindings regarding the effects of hyperuricemia on renal function and mortality have been inconsistent.ObjectivesTo investigate the effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease (CKD).Design And SettingRetrospective cohort study conducted in a medical center in Taiwan.MethodsPatients with CKD in stages 3-5, without histories of renal replacement therapy, were consecutively recruited from 2007 to 2013. Their medical history, laboratory and medication data were collected from hospital records. The mean uric acid level in the first year of follow-up was used for analyses. Hyperuricemia was defined as mean uric acid level ≥ 7.0 mg/dl in men or ≥ 6.0 mg/dl in women. The primary outcomes were incident renal replacement therapy and all-cause mortality, and these data were retrospectively collected from hospital records until the end of 2015.ResultsA total of 4,381 patients were analyzed (mean age 71.0 ± 14.8 years; males 62.7%), and the median follow-up period was 2.5 years. Patients with hyperuricemia were at increased risk of incident renal replacement therapy and all-cause mortality, especially those with CKD in stages 4 or 5. Compared with patients with CKD in stage 3 and normouricemia, patients with CKD in stages 4 or 5 presented significantly higher risk of all-cause mortality only if they had hyperuricemia.ConclusionsIn patients with CKD in stages 3-5, hyperuricemia was associated with higher risk of incident renal replacement therapy and all-cause mortality. Whether treatment with uric acid-lowering drugs in these patients would improve their outcomes merits further investigation.

26 keywords...

hide…